Related Experiment Videos
Predicting the need for adjuvant systemic therapy in patients receiving postprostatectomy irradiation
J D Forman1, M Duclos, F Shamsa
1Department of Radiation Oncology and Urology, Wayne State University, Detroit, MI 48201-2097, USA.
Urology
|March 1, 1996
Summary
Predicting prostate cancer recurrence after radiation is possible using clinical factors and PSA response. This helps avoid unnecessary treatments and toxicity for patients with elevated postprostatectomy PSA levels.
Area of Science:
- Oncology
- Radiation Oncology
- Urologic Oncology
Background:
- Postprostatectomy irradiation is used for rising or non-zero prostate-specific antigen (PSA) levels.
- Predicting treatment outcomes is crucial for guiding subsequent therapies.
Purpose of the Study:
- To identify clinical, pathologic, and biochemical predictors of treatment outcomes in patients receiving postprostatectomy irradiation.
- To determine if treatment outcomes can predict the need for further systemic therapy.
Main Methods:
- A cohort of 50 patients receiving external beam irradiation for elevated postprostatectomy PSA were analyzed.
- Univariate and multivariate logistic regression models were used to identify prognostic factors.
- Predictive accuracy and sensitivity of the developed model were assessed.
Main Results:
- Treatment was well-tolerated with minimal severe complications.
- 82% of patients experienced a PSA decline during irradiation, with 26% achieving a complete response.
- A multivariate model achieved 80% accuracy and 85% sensitivity in predicting outcomes, with clinical stage, preradiation PSA, and treatment response being significant factors.
Conclusions:
- Clinical stage, preradiation PSA, Gleason score, and treatment response accurately predict outcomes for patients with elevated postprostatectomy PSA undergoing irradiation.
- This predictive model can help identify patients who will not require additional hormonal therapy, thus avoiding unnecessary toxicity and cost.